Advice
following a full submission
naloxegol (Moventig®) is accepted for use within NHS Scotland.
Indication under review: the treatment of opioid-induced constipation in adult patients who have had an inadequate response to laxative(s).
Naloxegol compared to placebo significantly improved the response rate in patients with opioid-induced constipation including patients who had previously had an inadequate response to at least four days of treatment with at least one class of laxative.
Download detailed advice220KB (PDF)
Medicine details
- Medicine name:
- naloxegol (Moventig)
- SMC ID:
- 1106/15
- Indication:
- the treatment of opioid-induced constipation in adult patients who have had an inadequate response to laxative(s).
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Gastro-intestinal system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 07 December 2015